The resistance to drugs or problems in the management of CML is a function of the property and ability of the BCR-ABL oncogene to undergo mutations, develop mutant forms and BCR-ABL phenotypes1–8,12. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.